MAGE-1 (96-104)

MAGE-1 (96-104) is a synthetic peptide fragment derived from the melanoma-associated antigen 1 (MAGE-1) protein, specifically encompassing amino acid residues 96 through 104. This nonapeptide is recognized for its immunogenic properties and relevance in tumor antigen research, particularly in the context of melanoma and other malignancies expressing MAGE family proteins. As a well-characterized epitope, it plays a significant role in studies focused on antigen processing, immune recognition, and T cell activation. Its defined sequence and functional specificity make it a valuable reagent for advancing research in tumor immunology, peptide-based assay development, and cellular immune response investigations.

Epitope Mapping: In immunological research, the 96-104 peptide fragment of MAGE-1 is widely utilized for epitope mapping studies. By providing a defined minimal epitope, it enables researchers to examine the precise regions of MAGE-1 that are recognized by cytotoxic T lymphocytes (CTLs). Such studies are essential for understanding immune recognition mechanisms and for identifying the most immunogenic peptide sequences within larger tumor-associated antigens.

T Cell Activation Assays: The peptide serves as a robust tool in T cell activation and functional assays. When presented by appropriate major histocompatibility complex (MHC) molecules on the surface of antigen-presenting cells, it can stimulate MAGE-1-specific CTLs in vitro. This property is critical for evaluating T cell responses, monitoring immune reactivity, and optimizing protocols for ex vivo expansion of antigen-specific lymphocytes.

Peptide-MHC Binding Studies: It is frequently employed in binding affinity assays to assess the interaction between synthetic peptides and specific MHC class I molecules. Such studies are instrumental in elucidating the structural requirements for peptide presentation and stability, thereby informing the design of optimized peptide ligands for immunological applications. The MAGE-1 (96-104) sequence offers a model system for dissecting the molecular determinants of peptide-MHC recognition.

Cancer Immunology Research: As a representative tumor antigen-derived peptide, this fragment is extensively used in cancer immunology models to investigate mechanisms of tumor immune surveillance and immune escape. It facilitates the study of antigen processing, presentation pathways, and the development of immune-based detection systems for malignancies expressing MAGE-1. These insights contribute to the broader understanding of tumor-host interactions and the identification of novel immunotherapeutic targets.

Peptide-Based Assay Development: The defined structure and immunological relevance of MAGE-1 (96-104) support its use in the development and validation of peptide-based assays, including ELISPOT, flow cytometry, and tetramer staining techniques. These assays are vital for quantifying antigen-specific T cell populations, monitoring immune responses in experimental systems, and standardizing immunological measurements across research platforms. The peptide's sequence specificity and stability make it an ideal reference standard for such analytical applications.

1. C-Peptide replacement therapy and sensory nerve function in type 1 diabetic neuropathy

2. Cationic cell-penetrating peptides are potent furin inhibitors

3. Odorant binding protein based biomimetic sensors for detection of alcohols associated with Salmonella contamination in packaged beef

4. Genetic, cellular, and structural characterization of the membrane potential-dependent cell-penetrating peptide translocation pore

5. C-peptide and its C-terminal fragments improve erythrocyte deformability in type 1 diabetes patients